Instil Bio, Inc.
TILHealthcare|Biotechnology|US
$6.83
-0.16 (-2.29%)
Tangible Book / Share
$15.83
Cash / Share
$10.27
About
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Stock Price
-54.5%(1Y)
1M
+4.1%
3M
-7.8%
6M
-16.3%
YTD
-37.9%
1Y
-53.9%
3Y
-8.8%
5Y
-98.5%
Pipeline Summary
4 total trials3
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Terminated: 3Withdrawn: 1
Key Facts
Market Cap$46.3M
Employees17 (+21% YoY)
CEOBronson Crouch
IPO DateMar 19, 2021
Beta1.96
52-Week Range$5.56 – $16
Avg Volume24,894
ExchangeNASDAQ
Websiteinstilbio.com
Ownership
Float54.0%
Shares Outstanding6.8M
Recent Insider Trades
McGaughy R Kent JrAWARD
Jun 11, 20266,500 shares @ $7.93
Matcham GeorgeAWARD
Jun 11, 20266,500 shares @ $7.93
Gibson Neil WAWARD
Jun 11, 20260 shares @ $7.93
Binder GwendolynAWARD
Jun 11, 20266,500 shares @ $7.93
Laumas SandeepOPTION EX.
Sep 10, 202513,000 shares @ $12.68
Peers
Recent News
Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)
Oct 29, 2026 · globenewswire.com
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Oct 28, 2026 · globenewswire.com
Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
Oct 26, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:37 AM